fda warning letters compounded semaglutide september 2025 issued 25 to telehealth companies for false and misleading claims about GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of August 11, 2025: The FDA

Systemic administration of the neurotensin NTS-receptor agonist PD149163 improves performance on a memory task in naturally deficient male brown Norway rats

KG, Nmbrecht, Germany) at the following time points: 143 d ante injectionem (ai) (= d 42 ap , before L-carnitine supplementation), 11 d ai (= d 100 pp ), 24 h pi (= d 112 pp ) and 14 d pi (= d 126 pp )

doi: 10.3390/toxins11110665 130 BurrelloCGiuffreMRMacandogADDiaz-BasabeACribiuFMLopezGet al

Inclusion on the 503A Bulks List means the FDA has formally determined through rulemaking that a bulk drug substance may be used in compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act

[DOI] [PMC free article] [PubMed] [Google Scholar] [12].Lovell MA, Markesbery WR

T-cell receptors of CAR-T cells are artificially engineered to redirect them to a specific antigen